Our new AI-powered system unlocks novel LRRK2 inhibitors from vast chemical libraries, pushing the frontier of neurodegenerative drug discovery.
We’re proud to announce the filing of a provisional patent on January 4, 2025, for our cutting-edge virtual screening system: «BIOPTIC Ultra-High-Throughput Virtual Screening System».
This patent marks a critical step in Bioptic’s mission to deliver scalable, AI-native tools for drug discovery. It specifically covers our novel method of discovering LRRK2 ligands—a key target implicated in neurodegenerative diseases like Parkinson’s disease—using ultra-fast, ultra-large-scale molecular screening.
Why This Matters
LRRK2 (Leucine-rich repeat kinase 2) has been one of the most challenging yet high-potential targets in neurodegeneration. Traditional screening methods often fall short due to the vastness of chemical space and the need for high selectivity and brain permeability.
With our proprietary AI platform, we were able to:
- Screen billions of compounds in just minutes
- Predict binding affinities with high accuracy using our ligand- and sequence-based engines
- Rapidly identify novel scaffolds with strong IP potential and promising biological profiles
The Bigger Picture
This filing is part of our broader strategy to build AI-first infrastructure for discovering better drugs, faster. We believe such technology will become a backbone for therapeutic innovation — especially in fields where traditional approaches have reached their limits.
More details will be shared upon publication. In the meantime, this milestone reflects Bioptic’s continued leadership in applying high-throughput, target-agnostic AI to real therapeutic challenges.
